Takeda Pharmaceutical Company Limited

Solent Therapeutics, LLC

Mitsunori Kono

Satoshi Yamamoto

Tsuneo Oda

Naoki Ishii

Junya Shirai

Shoji Fukumoto

Yoshiyuki Fukase

Yoshihide Tomata

Atsuko Ochida

Hidekazu Tokuhara

Takashi Imada

Tomoya Yukawa

Michiko Tawada

Ayumu Sato

Yusuke Sasaki

Zhe Nie

Masaki Seto

Hiroyuki Watanabe

Betty Lam

Srinivasa Reddy Natala

Zenyu Shiokawa

Tony Gibson

Alison L Chambers

Steve Swann

Mark E Adams

Angie Vassar

Rongliang Chen

Simone Bigi

Jason Pickens

Feng Zhou

Matthew Lardy

Steven James Wilkens

Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R, R, R, Rand Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Heterocyclic amide compounds having an RORvt inhibitory action

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic amide compounds having RORyT inhibitory action

Amide compound

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

Heterocyclic compound

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Substituted 6-aza-isoindolin-1-one derivatives

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated. 

Growing community of inventors

Kanagawa, Japan

Mitsunori Kono